Dr. Molly M. Greenwade, MD

Dr. Greenwade practices at Cox North Hospital in Springfield, Missouri.

Dr. Greenwade's NPI, 1235574401, was assigned on May 1, 2013. Dr. Greenwade holds Missouri license 200046663.

Dr. Greenwade's primary practice is Cox North Hospital, at 1423 N Jefferson Ave, Springfield, MO 65802 in Greene County. The practice phone is (417) 269-6000.

Dr. Greenwade's primary practice is Cox North Hospital in Springfield, Missouri. Dr. Greenwade is also affiliated with Cox Medical Center South. The medical group on file is Ferrell-Duncan Clinic. Dmand AI also links Dr. Greenwade to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Greenwade practices, 4 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Greenwade's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Greenwade's licenses on file in 3 states: Missouri, Ohio and Oklahoma.

CMS data shows 134 Medicare services from Dr. Greenwade across 5 procedure codes in 2024, for 85 Medicare patients. Medicare paid $7,589 for them. Every service was in an office.

CMS counts 85 Medicare patients who saw Dr. Greenwade in 2024. The largest group is 65 to 74, with 43 patients. 71% of them have high blood pressure, and 56% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Greenwade's median patient age at 58, with 100% women.

In 2024, Dr. Greenwade wrote 200 Medicare Part D claims for 69 patients. 88% of them were for generic drugs. CMS names the drug for 112 of them, across 5 drugs with 11 or more claims each, at $239,894 in total drug cost. In 2023, CMS named 83 claims across 4 drugs.

Dr. Greenwade accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 17 procedures of removal of the uterus by Dr. Greenwade, more than 90% of the clinicians it reports for that procedure.

Dmand AI links 11 papers to Dr. Greenwade, published from 2016 to 2022. 2022 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms and Paclitaxel. Dr. Greenwade has published most often in Gynecol Oncol Rep. Dr. Greenwade's most frequent co-authors are David Mutch, DO, Premal Harish Thaker, MD and Katherine Cynthia Fuh, MD.

CMS Open Payments shows 133 general payments to Dr. Greenwade from 19 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 46% of the total. Abbvie Inc. paid the most, $1,909.